This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!
Case Study | October 25, 2021
Despite the value of AI to the pharmaceutical industry in the drug discovery space, significant barriers to its adoption remain. One of the major barriers lies in developing the relevant AI capabilities to tackle questions around novel target identification, lead identification and optimization, ... Not part of subscription
Company Profile | December 01, 2021
Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription
News Commentary | February 08, 2022
Pfizer has partnered with Stockholm‑based DTx (digital therapeutics) maker Alex Therapeutics to deploy artificial intelligence (AI)‑based digital therapeutics. The Alex DTx platform combines cognitive‑based therapy and acceptance and commitment therapy with AI to offer personalized treatment plans. ... Not part of subscription